5-[p-(Substituted)phenyl]-2,2-dialkyl-4-phenyl-3-oxazoline
US4360530A · kind A · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 1981 |
| Grant date | Nov 23, 1982 |
| Priority date | — |
| Expiry date | Nov 12, 2001 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D263/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2, independently, are hydrogen, halogen or lower alkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; R.sup.8 is hydrogen, lower alkyl or formyl; R.sup.9 and R.sup.10, independently, are methyl or trifluoromethyl; and n is 0 (zero) or, when both R.sup.7 and R.sup.8 are lower alkyl, n is 0 (zero) or 1, prepared, inter alia, from p-aminobenzaldehydes which may be N-alkyl substituted, are described. The compounds of formula I are orally active antidiabetic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.